Background/Aims: Long non-coding RNAs (lncRNAs) have been reported to play pivotal roles in multiple tumors and can act as tumor biomarkers. In this study, we explored the association of the expression of an lncRNA, DGCR5 with clinicopathological features and prognosis in HCC. Methods: Expression levels of DGCR5 were detected by quantitative real-time PCR (qRT-PCR) and the clinical data was obtained, including basic information, data of clinicopathology and cancer specific survival rate. Receiver operating characteristic (ROC) curve, Kaplan-Meier methods and multivariable Cox regression models were used to analyze predictive efficiency, long-term survival outcomes and risk factors. Results: DGCR5 was found down-regulated in HCC tissues (P<0.001) and serum (P = 0.0035) and low expression of DGCR5 was correlated with a poor cancer specific survival (CSS) (P = 0.0019), as the overall 5-year CSS rates were 10.3% (low expression group) and 36.6% (high expression group), respectively. A stratified analysis demonstrated that low DGCR5 expression was an independent negative prognostic factor for HCC. In addition, the area under the ROC curve was 0.782 with a sensitivity of 0.633 and a specificity of 0.833. Conclusions: Our results suggest that DGCR5 may be a participator in HCC and can serve as potential biomarker for the diagnosis and prognosis in HCC.
Introduction
Liver cancer is the second most common cause of cancer-associated death worldwide, accounting for nearly 745,500 deaths in 2012 (9.1% of the total) [1] . Hepatocellular carcinoma (HCC), which occupied 70-90% of primary liver cancer, is characterized by performed at 80 V for 40 min, with 0.5% Tris-acetate-EDTA (TAE) as the running buffer. Data were analyzed with Image Lab software performed with an ultraviolet (UV) transilluminator.
Table 1. Primer sets used for quantitative RT-PCR

Follow-up for survival
In the study, all the patients were followed-up regularly for survival analysis until death or cut-off date of study. During the follow-up period, abdominal doppler ultrasound and CT for every 3 months for 2 years. And in years 3 to 5, examinations conducted at 6 months intervals and annually thereafter.
Statistical analysis
All statistical analyses were performed using SPSS 18.0 (SPSS Inc, Chicago, IL, USA) software and presented with the GraphPad prism software (GraphPad Software, San Diego, CA, USA). Results of quantitative real-time PCR were expressed as mean ± S.E.M. The Student's t test and the Chi-square (χ 2 ) test were used to evaluate statistical differences of DGCR5 expression in different samples and e xamine the relationship between DGCR5 expression and clinicopathological features. The cancer specific survival (CSS) of patient was estimated using the Kaplan-Meier method. Analysis of area under the receiver operating characteristic (ROC) curve (AUC) was used to estimate the effectiveness of DGCR5 f or prediction. In all cases, P < 0.05 was considered statistically significant.
Results
Down-regulation of DGCR5 in HCC
Compared to adjacent non-tumor tissues (n = 110), DGCR5 was aberrantly d ecreased (P<0.001) in tumor tissues (n = 110), detected by qRT-PCR (Fig. 1A) . Furthermore, DGCR5 expression levels in serum from patients with HCC (n = 60) were reduced (P = 0.0035) in comparison with healthy controls (n = 60) (Fig. 1B) . These data reveal that DGCR5 might play a pivotal role in HCC progression.
Correlation of DGCR5 expression with clinicopathological features
In order to investigate the relationship between DGCR5 expression and clinicopathological features in HCC, the median expression level of DGCR5 in HCC tissues was used to separated the patients into low expression group (n = 65) and high expression group (n = 65) (Fig. 1C) . As illustrated in Table 2 , we found the DGCR5 expression was obviously associated with HbsAg (P = 0.039) and vascular invasion (P = 0.003). However, other clinical factors, such as age, tumor size and histology grade, suggested no significant association with DGCR5 expression.
Association of DGCR5 expression and cancer specific survival
The 5-year liver cancer specific survival rates were 10.3% and 36.6% in low expression and high expression groups, respectively. Univariate analysis showed that larger tumor (P = 0.017), poor/undifferentiated grade (P < 0.001) and low expression of DGCR5 (P = 0.002) were significant risk factors for poorer prognosis. Furthermore, Edmondson grade (III-IV, HR 2.939, 95% CI 1.757-4.916, P < 0.001) and DGCR5 expression (high, HR 0.506, 95% CI 0.310-0.825, P = 0.006) were found to be independent prognostic factors by multivariate analysis (Table 3) .
DGCR5 as a biomarker for HCC diagnosis and prognosis
We further analyzed relationship between the expression of DGCR5 and prognosis and diagnosis by Kaplan-Meier method, log-rank test and ROC curve. The median survival periods were 33 months and 45 months in low expression and high expression groups.
As shown in Fig. 2A , low expression of DGCR5 was correlated with a shorter CSS (P = 0.0019). Our results also showed that the area under the curve (AUC) was 0.782 and DGCR5 may be an effective predictor for HCC diagnosis with a sensitivity of 0.633 and a specificity of 0.833 (Fig. 2B) .
Then, we amplified DGCR5 in healthy controls and detected the amplification by agarose gel electrophoresis. Our results indicated that DGCR5 were detectable in human serum. Serum samples were frozen and thawed for five times or incubated at room temperature for 0, 12, 24 and 48 hours, and expression of DGCR5 in serum detected by agarose electrophoresis and qRT-PCR indicated that DGCR5 was stably expressed in serum (Fig. 3) . Table 2 . Correlation between DGCR5 expression and clinicopathological characteristics of HCC patients (n = 110). HBsAg: hepatitis B surface antigen. For the expression of DGCR5, median expression level in HCC tissues was used as the cutoff. Data were analyzed by chi-squared test.* indicates statistically significant samples. (C) The HCC patients included in the study were divided into a high DGCR5 expression group and a low DGCR5 expression group according to the median value of relative DGCR5 expression in HCC tissues. Each experiment was performed in triplicate. (** P < 0.01, *** P < 0.001).
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Discussion
Primary liver cancer is a major health problem worldwide and famous for its malignancy, with an estimated 782,500 new cases and 745,500 deaths occurred yearly [1] . 70-90% of primary liver cancer is HCC, and about 50% of the total number of cases and deaths occurred in China. In the past decade, HCC incidence is increasing because of the rising incidence in Western Europe and Northern America [6, 23, 24] . In the USA, the incidence rate of HCC increased from 2.6 per 100,000 to 8.6 per 100,000 between 1975 and 2011 [1] .
In recent years, the prognosis for HCC has improved because more patients could be diagnosed at early stages and great advances had Table 3 . Univariate and multivariate survival analyses evaluating DGCR5 expressing influencing CSS in HCC. NI: not included in multivariate survival analysis. For the expression of DGCR5, median expression level in HCC tissues was used as the cutoff. All the results were adjusted using Cox proportional hazards models for tumor size, Edmondson grade and DGCR5 expression. * indicates statistically significant been made in treatments for HCC, including liver resection, early-stage radiofrequency ablation and curative transplantation [25] . Clinical research has revealed that patients, treated at the early stages, had good prognosis and high overall survival rate [26, 27] . Pacella et al. [28] showed that the median overall survival duration was significantly longer in patients with main tumor size of <2.0 cm (56 months, 95% CI, 46 to 66 months) versus 3.1 to 4.0 cm (35 months, 95% CI, 25 to 37 months). In a study of 8455 HCC patients, Zhang et al. [24] demonstrated that tumor size was still an important independent prognostic factor and the 36-and 60-month CSS rates dropped sharply when the tumor size reached 35 mm. Therefore, identification of novel serum biomarkers for detecting and screening in earlystage cancer is an important goal in the diagnosis of HCC.
However, due to absence of symptoms in early phase, HCC patients were mostly diagnosed at an advanced stage still with a high mortality and a lower 5-year survival rate [6] . In addition, the main plasma tumor marker for HCC, AFP was raised in 11-58% of patients with chronic hepatitis or cirrhosis without HCC, and 30-40% of all patients with HCC were AFP negative [29, 30] .
LncRNAs have been found deregulated in lots of diseases, especially in neoplastic disease [31, 32] , and accumulating studies have demonstrated that LncRNAs could act as tumor biomarkers [33, 34] . H19, SNHG16, TUG1 and UCA1 were detected deregulated in bladder cancer and confirmed to be used as diagnostic markers or prognostic markers [10] . Gutschner et al. [35] demonstrated that MALAT1 was a biomarker for lung cancer metastasis and prognosis through regulating gene expression governing hallmarks of metastasis. There are several lncRNAs that have been proved to be relevant to the development and progression of HCC. Previous studies reported that Linc00974 and Linc00152 promoted 
(C) Receiver operating characteristic curve analysis was used to evaluate the diagnosis value of DGCR5 for HCC. Area under the curve (AUC) was 0.769 with a sensitivity of 0.683 and a specificity of 0.8. receptor-dependent pathway. DGCR5 is a human non-coding RNA located at chromosome 22q11 with 3334 bp (http://www.ncbi.nlm.nih.gov/gene/26220). However, the role of DGCR5 in the clinicopathology and prognosis in HCC has not been reported.
In the present study, we found that DGCR5 was significantly down-regulated in HCC tissues compared with that in adjacent non-tumor tissues, which was consistent with the Oncomine database ( P<0.05). More important, we found that the median survivals were 33 months and 45 months in low expression and high expression group, respectively. Low expression of DGCR5 was significantly associated with a shorter CSS, which suggested that DGCR5 has important functions in the progression of HCC. All above study revealed that DGCR5 may be a promising biomarker for the prognosis in HCC. Thus, we detected serum DGCR5 expressing and found that DGCR5 expressing was significantly down-regulated in serum from patients with HCC than in that from healthy controls. Therefore, DGCR5 may serve as potential biomarker for predicting the diagnosis in HCC. To confirm this, ROC curve analysis was used and the result showed the evidence for great value of DGCR5. The area under the ROC curve of DGCR5 (0.782), with a sensitivity of 0.633 and a specificity of 0.833, is similar to that of AFP (0.769) with a sensitivity of 0.683 and a specificity of 0.8 (Fig. 2C) .
Univariate analysis showed that patient with large tumor, poorly or undifferentiated grade and low DGCR5 expression had a poor 5-year CSS. As pivotal factors, the associations of tumor size and differentiated grade with survival had been analyzed widely in HCC. Takayasu et al. [37] demonstrated that the prognosis of patients with HCC was associated with tumor size in a cohort of 8,510 patients. In a study included 788 patients, Nathan et al. [38] showed that pathologic staging was still an important independent prognostic factor. Similar results were also reported by Zhang and his colleagues [24] . In this study, we identified median value of DGCR5 in HCC tissues as the cutoff to divide patients into two subgroups. The 5-year CSS rates were 10.3% and 36.6% in the low DGCR5 group and high DGCR5 group, respectively, and low DGCR5 expression was a risk factor for poor survival. Further stratified analysis demonstrated that Edmondson grade and DGCR5 expression were validated as independent prognostic factors of survival in multivariate Cox regression.
In summary, our study revealed DGCR5 expression was down-regulated in HCC patients and can serve as a potential biomarker for the diagnosis and prognosis in HCC. However, the molecular mechanisms of DGCR5 that involved in HCC need to be further studied.
